Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.
SRPT SEC Filing Email Alerts Service
Company Name: |
Sarepta Therapeutics Inc |
Website: |
www.sarepta.com |
Sector: |
Biotechnology |
Number of ETFs Holding SRPT: |
38 |
Total Market Value Held by ETFs: |
$1.20B |
Total Market Capitalization: |
$11.01B |
% of Market Cap. Held by ETFs: |
10.91% |
|
|
April 20, 2024 5:11 AM Eastern
Strong Buy (3.50 out of 4)
100th percentile
|
|